Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

December 18, 2013 updated by: Jonsson Comprehensive Cancer Center

A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Biological therapies such as CpG 7909 use different ways to stimulate the immune system and stop cancer cells from growing. Combining CpG 7909 with rituximab may kill more cancer cells.

PURPOSE: Phase I trial to study the effectiveness of CpG 7909 plus rituximab in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

  • Determine the maximum tolerated dose of subcutaneous and IV CpG 7909 when administered with rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
  • Determine the safety and tolerability of this regimen in these patients.
  • Determine the disease response in patients treated with this regimen.

OUTLINE: This is a multicenter, dose-escalation study of CpG 7909. Patients are sequentially assigned to 1 of 2 treatment groups.

  • Group A: Patients receive rituximab IV over 4-5 hours followed by CpG 7909 IV over 2 hours on day 1. Courses repeat weekly for 4 weeks.
  • Group B: Patients receive rituximab as above followed by CpG 7909 subcutaneously on day 1. Courses repeat weekly for 4 weeks.

Cohorts of 3-6 patients receive escalating doses of CpG 7909 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 6-48 patients (3-24 per treatment group) will be accrued for this study.

Study Type

Interventional

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90095-1781
        • Jonsson Comprehensive Cancer Center, UCLA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

DISEASE CHARACTERISTICS:

  • Histologically confirmed CD20+ B-cell non-Hodgkin's lymphoma (NHL)

    • CD20 positive by immunohistochemistry or flow cytometry
  • Relapsed or refractory disease

  • Bidimensionally measurable disease

    • Sole site of measurable disease within a previously irradiated field allowed provided there was disease progression at that site
  • No pre-existing ascites or pleural effusions
  • No known CNS involvement by NHL

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • More than 3 months

Hematopoietic:

  • Neutrophil count at least 1,000/mm3
  • Platelet count at least 50,000/mm3

Hepatic:

  • Bilirubin less than 2 mg/dL
  • Transaminase less than 2 times upper limit of normal
  • No hepatitis B or C

Renal:

  • Creatinine less than 2 mg/dL

Cardiovascular:

  • No significant cardiovascular disease
  • No New York Heart Association class III congestive heart failure
  • No myocardial infarction within the past 6 months
  • No unstable angina
  • No uncontrolled atrial or ventricular cardiac arrhythmias

Pulmonary:

  • No concurrent significant pulmonary disease

Other:

  • HIV negative
  • No acute infection requiring antibiotics
  • No fever over 38.2 degrees C within the past 3 days
  • No other malignancy within the past 5 years except basal cell or noninvasive squamous cell skin cancer or carcinoma in situ of the cervix

  • No pre-existing autoimmune disease or antibody-mediated disease, including:

    • Systemic lupus erythematosus
    • Rheumatoid arthritis
    • Multiple sclerosis
    • Sjogren's syndrome
    • Autoimmune thrombocytopenia
  • Controlled thyroid disease allowed
  • Concurrent autoantibodies without clinical autoimmune disease allowed
  • No history of allergic reactions attributed to compounds of similar composition to study drugs
  • No other medical history, including laboratory results, that would preclude study
  • No suspected or confirmed poor compliance or mental instability that would preclude study
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior allogeneic transplantation
  • More than 30 days since prior hematopoietic growth factors (e.g., filgrastim (G-CSF) or epoetin alfa)
  • More than 30 days since prior immunotherapy
  • More than 90 days since prior monoclonal antibodies as monotherapy for patients who were unresponsive to treatment (30 days for patients who responded to treatment and subsequently relapsed)
  • No other concurrent biological agents
  • No concurrent hematopoietic growth factors (e.g., G-CSF or epoetin alfa)

Chemotherapy:

  • More than 30 days since prior chemotherapy
  • No concurrent chemotherapy

Endocrine therapy:

  • More than 30 days since prior systemic corticosteroids
  • No concurrent systemic corticosteroids

Radiotherapy:

  • See Disease Characteristics
  • More than 30 days since prior radiotherapy
  • No concurrent radiotherapy

Surgery:

  • Not specified

Other:

  • Recovered from prior therapy
  • At least 6 months since prior coronary angioplasty
  • More than 30 days since prior immunosuppressants
  • More than 30 days since prior participation in an investigational drug study
  • No concurrent immunosuppressants
  • No concurrent anticoagulants except aspirin at doses no greater than 325 mg/day
  • No other concurrent anticancer therapy
  • No other concurrent investigational agents

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

National Cancer Institute (NCI)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2002

Study Completion (Actual)

October 1, 2007

Study Registration Dates

First Submitted

July 8, 2002

First Submitted That Met QC Criteria

January 26, 2003

First Posted (Estimate)

January 27, 2003

Study Record Updates

Last Update Posted (Estimate)

December 19, 2013

Last Update Submitted That Met QC Criteria

December 18, 2013

Last Verified

July 1, 2003

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CDR0000069423
  • UCLA-0112032
  • CPGI-C004-CPG7909
  • NCI-G02-2086

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Clinical Trials on rituximab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe